Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177317 | 0.87 | DRD2 (0.44) | CCR4DRD2DRD4DRD3PPARG | |
| SCHEMBL2178011 | 0.85 | CCR4 (0.38) | CCR4DRD2DRD4DRD3PPARG | |
| SCHEMBL2175710 | 0.84 | MAPT (0.40) | CCR4PPARGNPC1ALDH1A1MAPT | |
| SCHEMBL2175171 | 0.84 | CCR4 (0.39) | CCR4DRD2DRD4DRD3PPARG | |
| SCHEMBL2174669 | 0.84 | CCR4 (0.37) | CCR4DRD2DRD4DRD3PPARG | |
| SCHEMBL2174575 | 0.83 | MTNR1A (0.38) | CCR4PPARGNPC1ALDH1A1MAPT | |
| SCHEMBL2178339 | 0.83 | CCR4 (0.38) | CCR4PPARGMCHR1MAPK14NPC1 | |
| SCHEMBL2176002 | 0.82 | CCR4 (0.41) | CCR4DRD2PPARGMCHR1MAPK14 | |
| SCHEMBL2177786 | 0.82 | CCR4 (0.37) | CCR4PPARGMCHR1NPC1ALDH1A1 | |
| SCHEMBL2177619 | 0.82 | MCHR1 (0.43) | CCR4DRD3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | CCR4 4278/4885DRD2 4103/4885DRD4 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.